Lexeo Therapeutics
Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.
-
Gene therapy targets deadly heart damage in rare neurological disease
Disease control OngoingThis early-stage trial is testing whether a single dose of LX2006 gene therapy can safely treat heart muscle damage in people with Friedreich's ataxia. The therapy delivers a healthy gene directly to heart cells to improve their function. Eight participants with confirmed Friedre…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
First human test of gene therapy for inherited heart disease
Disease control OngoingThis is a first-in-human study to test the safety and early effectiveness of a new gene therapy called LX2020. It is for adults with a specific genetic form of arrhythmogenic cardiomyopathy, a heart condition that can cause dangerous irregular heartbeats. The therapy is given thr…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists track patients for years after pioneering heart gene therapy
Disease control ENROLLING_BY_INVITATIONThis study is a long-term follow-up for up to 10 patients who previously received an experimental gene therapy (LX2020) for a genetic heart muscle disease. The main goal is to monitor their health for four more years to check for any long-term side effects. No new treatment is gi…
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC